drugset / Trial / NCT02185040

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

NCT02185040

Phase 2 Completed 42 enrolled Celgene Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.

Timeline

Start
2014-09-16
Primary completion
2018-09-25
Completion
2018-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Iberdomide Small molecule 0.3 mg Oral
Subject Iberdomide Small molecule 0.6 mg Oral